ArticleInternational journal of antimicrobial agents2020
Is teicoplanin a complementary treatment option for COVID-19? The question remains.
Article in International journal of antimicrobial agents, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Post-Traumatic Stress Symptoms in Healthcare Workers Dealing with the COVID-19 Pandemic: A Systematic Review.International journal of environmental research and public health · 2021Pooled it
- Can treatment with teicoplanin improve the prognosis of COVID-19 patients?International journal of clinical practice · 2021Trial
- Potential Drugs in COVID-19 Management.Current medicinal chemistry · 2024Review
- Severe COVID-19: Drugs and Clinical Trials.Journal of clinical medicine · 2023Review
- Self-association of the glycopeptide antibiotic teicoplanin A2 in aqueous solution studied by molecular hydrodynamics.Scientific reports · 2023Article
- A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.Narra J · 2022Review
- Antimicrobial peptides: A plausible approach for COVID-19 treatment.Expert opinion on drug discovery · 2022Review
- Clinical effect of teicoplanin on pulmonary infection after chemotherapy for hematologic malignancies.American journal of translational research · 2022Article
- Covid 19-the 21st Century Pandemic: The Novel Coronavirus Outbreak and the Treatment Strategies.Advanced pharmaceutical bulletin · 2022Review
- Teicoplanin-A New Use for an Old Drug in the COVID-19 Era?Pharmaceuticals (Basel, Switzerland) · 2021Review
- New Insights Into Drug Repurposing for COVID-19 Using Deep Learning.IEEE transactions on neural networks and learning systems · 2021Review
- Comparison of clinical features and outcomes in COVID-19 and influenza pneumonia patients requiring intensive care unit admission.Infection · 2021Article
- Available drugs and supplements for rapid deployment for treatment of COVID-19.Journal of molecular cell biology · 2021Article
- Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study).Journal of medical virology · 2021Observational
- The importance of genomic analysis in cracking the coronavirus pandemic.Expert review of molecular diagnostics · 2021Review
- Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection.Diagnostic microbiology and infectious disease · 2021Article
- Repurposing of antibiotics for clinical management of COVID-19: a narrative review.Annals of clinical microbiology and antimicrobials · 2021Review
- Ongoing COVID-19 Pandemic: A Concise but Updated Comprehensive Review.Current microbiology · 2021Review
- Potential drug targets of SARS-CoV-2: From genomics to therapeutics.International journal of biological macromolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.